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Abstract
Background:  Vascular targeting of malignant tumors has become a clinically validated new
treatment approach with clear patient benefit. However clinical studies have also revealed that
some types of vascular targeting agents (VTAs) are prone to coagulation system side effects. It is
therefore essential to predetermine coagulation parameters in preclinical studies. As of to date, this
has rarely been done, predominantly due to technical issues.
The goal of this study was to establish and apply a standardized process, whereby systemic
coagulation activation can be routinely measured in mice.
Results: We have evaluated a number of sampling techniques and coagulation tests regarding their
suitability for this purpose. We were able to adapt two assays measuring soluble fibrin, a marker
for a prethrombotic status. Thus, soluble fibrin could be measured for the first time in mice. All
assays were validated in a positive control model for systemic coagulation activation, i.e.
lipopolysaccharide-induced endotoxemia.
Based on our results, we selected a panel of coagulation tests, which are both feasable and
informative for preclinical testing of VTAs: soluble fibrin, thrombin-antithrombin complexes, free
antithrombin III, white blood cell counts and platelet counts. The effect of tumor transplants on
coagulation parameters was evaluated using this panel. We then applied this set of assays in
treatment studies with a VTA developed in our laboratory to investigate a potential systemic
coagulation activation.
Conclusion: We have established a standardized panel of assays that can be used to test murine
blood samples for coagulation activation in preclinical studies. All tests are feasible to perform in
any research laboratory without specialized equipment. In addition, this is the first report to
measure soluble fibrin, an early marker of systemic coagulation activation, in mice. The panel was
applied on tumor bearing mice and mice treated with a VTA. We suggest its general application for
coagulation activation analyses in mice.
Background
The tumor vasculature has been recognized as a promising
target for new treatment approaches such as angiogenesis
inhibitors, vascular disrupting agents and specific vascular
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occluding agents [1-5]. A number of these vascular target-
ing agents (VTAs) have been evaluated in clinical trials
and prolongation of survival has been demonstrated in a
phase III trial [6]. However in several studies serious side
effects on the coagulation system, such as myocardial inf-
arction, thrombembolic complications and fatal bleed-
ings have been observed [7-11]. In addition, in cancer
patients the underlying disease can also interact with the
coagulation system [reviewed in [12]].
Therefore, assessment of coagulation parameters is of
importance in preclinical trials studying the effect of VTAs
as anti-cancer agents.
Surprisingly few data are available on coagulation param-
eters in preclinical VTA-treatment studies in mice. This
seems to be predominantly due to technical challenges:
Sample volumes in mice are small; artifacts are easily
introduced; and the number of tests which are suitable for
murine samples is limited because most commercially
available coagulation assays designed for use in humans
are not applicable in mice [13]. Extensive coagulation
studies have therefore been restricted to larger animals,
such as rabbits, rats and dogs [14-16]. However mice are
the species most widely used for preclinical studies in
experimental oncology.
Although there is a vast amount of literature on mouse
models concerning thrombosis or lipopolysaccharide
(LPS)-induced disseminated intravascular coagulation
(DIC), in most studies only a few coagulation parameters
were measured simultaneously. The lack of consistency in
the selected parameters makes a comparison between dif-
ferent reports difficult [16-24]. Also technical issues such
as sampling techniques and anticoagulant additives vary:
In some experiments blood is sampled by Vena cava punc-
ture [25], in others by heart puncture or by tail cut
[26,27], and citrate:blood ratios of 1:10 or 1:5 have been
reported.
In this study, we have set out to establish a standardized
process for the measurement of potential side effects of
drugs, that might affect the coagulation system. In addi-
tion to optimizing technical issues, we wanted to assem-
ble a panel of tests, that would i) detect coagulation
changes with a focus on systemic coagulation activation,
ii) be suitable for murine samples, iii) be feasable to per-
form routinely in a large number of samples and iv) be
preferentially available commercially. The tests evaluated
here were: Prothrombin time (PT), a global coagulation
marker indicative of changes in the extrinsic and the com-
mon pathway; activated partial thromboplastin time
(aPTT), a global marker indicative of changes in the intrin-
sic and common pathway; soluble fibrin (SF), a sensitive
marker of systemic coagulation activation; thrombin-anti-
thrombin complexes (TAT), a marker of systemic coagula-
tion activation; functional antithrombin III (ATIII), which
is reduced in consumption coagulopathy; white blood cell
counts (WBC), which show a specific pattern of change
over time in DIC [28]; platelet counts (PLT), which are
typically reduced in DIC; and schistocyte counts, i.e. frag-
mented erythrocytes, which can also be indicative of DIC.
Soluble fibrin (SF) had not been measured in mice,
although it was found to be a useful marker for a pre-
thrombotic state in humans [29-31]. SF occurs after
thrombin cleavage of fibrinogen. It is not a clearly defined
homogenous molecule but rather describes various fibrin
compounds of different molecular structures, including
fibrin monomers, polymers and crosslinked fibrin. In the
past, a number of assays detecting soluble fibrin were
developed [reviewed in [32]]: Gelation tests with ethanol
or protamine [33,34], chromatographic analysis [35],
Western Blotting of fibrin related compounds [35,36],
Table 1: Comparison of sampling techniques for different coagulation parameters: Vena cava puncture (VCP) vs tail cut (TC) as 
measured by Prothrombin Time (PT) and activated Partial Thromboplastin Time (aPTT) in plasma of untreated negative control 
mice
Assay: PT mean (SD) aPTT mean (SD) number of samples 
not evaluable
number of samples 
analyzed
% of samples not 
evaluable
Sampling 
technique:
[s] [% of standard]* [s] [n] [n] [%]
VCP 1:5 9.2 (1.0) 94 (10) 31.7 (4.6) 3 15 20%
VCP 1:10 7.8 (0.1) 116 (13) 23.2 (0.8) 0 10 0%
TC 1:5 - - - 3 3 100 %
TC 1:10 - - - 4 4 100 %
Ref.values: 8–10 80–120 32–36/23–25†
* where the clotting time of a normal plasma standard was defined as 100%
† normal values depended on citrate:blood ratio, and were 32–36 s for 1:5 ratio and 23–25 s for 1:10 ratioThrombosis Journal 2005, 3:21 http://www.thrombosisjournal.com/content/3/1/21
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immunological methods such as ELISAs or latex aggluti-
nation assays [37] and functional assays. The former are
neither very sensitive nor suited for routine analysis, while
the immunological methods are species specific and do
not crossreact with murine samples (13, own data).
Among the functional tests, two different principles have
been exploited for test development: i) the agglutination
reaction of fibrin-coated erythrocytes with SF in plasma
samples [38], and ii) the ability of SF to accelerate the tPA
(tissue plasminogen activator)-catalyzed cleavage of plas-
minogen to plasmin [39]. These two tests were developed
for human samples and made commercially available.
Initially they were not suited for testing murine samples,
therefore we modified them for the use in mice.
We then selected a panel of assays suited for testing sys-
temic coagulation assays in mice. This test series was
applied in mouse models to investigate the impact of
tumor transplants on the coagulation system, and to pre-
determine potential side effects caused by VTAs.
Results
Blood sampling from the tail vein or heart introduces 
artifacts
Three different sampling techniques were compared in
untreated control mice: tail cut, heart puncture and Vena
cava puncture. Tables 1 and 2 summarize the results.
Table 1 shows a comparison of results from measure-
ments of PT and aPTT in samples obtained either by Vena
cava puncture or by tail cut. Citrate dilutions of 1:5 and
1:10 were used as indicated. None of the samples
obtained by tail cut were evaluable because they coagu-
lated prior to the test. As expected, the clotting times for
1:5 and 1:10 citrate dilutions differed slightly. The sam-
ples diluted with citrate at a 1:5 citrate:blood ratio showed
a high standard deviation, and some samples were not
evaluable at all. This was most likely due to a relative lack
of Ca++ ions. Adjusting the Ca++ ion concentration might
have circumvented this problem. However, due to the
high sample volume required for PT and PTT measure-
ments, plasma samples could not be analyzed simultane-
ously for PT/PTT and for the panel of SF, ATIII, TAT, WBC
and PLT. Therefore it was not necessary to use the 1:5 cit-
rate:blood ratio, when analyzing PT and PTT. Similarly,
when we analyzed samples for thrombin-antithrombin
complexes or soluble fibrin, samples obtained by tail cut
were either not evaluable or showed systemic coagulation
activation (data not shown). In conclusion, tail cut seems
to be an unsuitable blood sampling method for coagula-
tion parameter analysis.
In Table 2, a comparison of results from soluble fibrin
(SF) determinations in Vena cava puncture samples and
heart puncture samples at different citrate:blood ratios are
shown. Only samples obtained by Vena cava puncture at a
1:5 citrate:blood ratio were negative for SF, as expected in
untreated mice. Since assays for TAT, WBC and PLT could
also be successfully performed using this sampling tech-
nique (data not shown), Vena cava puncture at a cit-
rate:blood dilution factor of 1:5 was our preferred
sampling method (with the possible exception of PT and
aPTT).
Measurement of SF in mice
First we induced SF in vitro by treatment of murine or
human plasma with thrombin, and verified that SF forma-
tion had taken place using Western Blotting (Figure 1A).
Two functional assays developed to measure SF in human
samples were then adapted for the use in mice:
The erythrocyte agglutination assay is an easily performed
test kit, which measures SF in a semiquantitative fashion.
When we carried it out according to the manufacturers
instructions, but using murine samples, we observed
Table 2: Comparison of sampling techniques for different coagulation parameters: Vena cava puncture (VCP) vs heart puncture (HP) 
as measured by Soluble Fibrin in plasma of untreated negative control mice
Number of mice 
negative
Number of mice with 
borderline result
Number of mice 
positive
Number of mice 
analyzed
Number of positive 
results in negative 
control mice
s a m p l i n g  t e c h n i q u e : nnnn%
V C P  1 : 5 1 71 01 8 0  %
VCP 1:10 10 2 5 17 29%
H P  1 : 5 0055 1 0 0 %
HP 1:10 3 0 10 13 77%
Ref.values: neg‡
‡ negative, if no further manipulations are performed. If reagents are administered i.v., there can be up to 30% positive samples, independent of the 
reagent applied (see Fig. 2).Thrombosis Journal 2005, 3:21 http://www.thrombosisjournal.com/content/3/1/21
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agglutination reactions in our negative control samples
(normal mouse plasma). This was most likely due to an
unspecific bridging factor. However, after varying assay
conditions (dilution of plasma, reagent volumes and rea-
gent conditions) we were able to eliminate the unspecific
agglutination. Using the optimized protocol as described
in the methods part, the positive controls, i.e. thrombin-
treated samples, which had been shown by Western Blot-
In vitro generation and measurement of murine soluble fibrin Figure 1
In vitro generation and measurement of murine soluble fibrin. A. Western Blotting. Murine plasma samples were 
treated with 0.02 U/ml thrombin and separated via gel electrophoresis under non-reducing (upper panel) and reducing (lower 
panel) conditions. Fibrin(ogen) was detected with a polyclonal anti-fibrinogen antibody. Lanes 1, 3: plasma without thrombin 
treatment. Lanes 2, 4: thrombin-treated plasma. Lane 1: Arrowhead points at undigested 340 kDa fibrinogen hexamer (αβγ)2. 
Lane 2: upper band depicts high molecular weight cross linked fibrin (XLF), lower band represents remaining undigested fibrin-
ogen. Lane 3: Arrowhead points at fibrinogen monomers consisting of α- (64 kDa, not visible), β-(56 kDa) and γ- (47 kDa) 
chains. Lane 4: formation of α-chain dimers (α-α, weakly stained) and γ-chain dimers (γ-γ); lower band represents fibrinogen β- 
chains and remaining non cross-linked γ-chains. B. Agglutination test for soluble fibrin. The same samples as in A were evalu-
ated with the SF agglutination test as described in the Methods section. 1: Untreated plasma samples show no agglutination. 2: 
Thrombin-treated plasmas agglutinated and gave a positive test result. C. Semiquantitative measurement of soluble fibrin. 
Murine plasma samples were treated with different amounts of thrombin (100 mU/ml, 50 mU/ml, 25 mU/ml, 10 mU/ml, 6 mU/
ml and 0 mU/ml as indicated). For a direct comparison with the chromogenic assay shown in panel D, and in contrast to the 
regular agglutination test protocol, thrombin was added before dilution of the sample in Owren's buffer followed by incubation 
at 37°C for 10 min. The amount of thrombin used for activation of the plasma correlated with the agglutination reaction, thus 
allowing for semiquantitative evaluation of test results. D. Quantitative analysis of soluble fibrin by a chromogenic assay. Murine 
plasma samples were treated with different amounts of thrombin and absorption at 405 nm was correlated with the thrombin 
concentration used to induce soluble fibrin. There was a linear relationship beween 15 mU/ml and 50 mU/ml thrombin.
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ting to contain SF, showed an agglutination reaction,
which was not observed in negative control samples
(untreated normal mouse plasma). This is demonstrated
in Figure 1B. We then treated plasma samples with various
doses of thrombin, resulting in corresponding amounts of
SF. Figure 1C illustrates that the agglutination reaction
was visibly stronger in the presence of higher amounts SF,
yielding a semiquantitative evaluation.
The chromogenic assay is more difficult and time con-
suming. It originally was developed for automated meas-
urements, but we established a manual procedure which
measured 12 samples per test. Positive controls for the
standard curve and negative controls were generated as
described in the Methods section. The standard curve was
linear for normal mouse plasma standards treated with 15
mU/ml to 50 mU/ml thrombin. Thus, within this range,
sample values could be quantitated in arbitrary units cor-
responding to the amount of activating thrombin (Figure
1D). A direct conversion into µg/ml SF was not possible,
because human plasma reacted differently than mouse
plasma (data not shown), and therefore the human stand-
ards provided in the kit could not be used in the murine
setting.
The detection limits were comparable for the agglutina-
tion assay and the chromogenic assay (Figure 1C, D). Pos-
itive controls of the chromogenic assay test kit were also
positive in the agglutination test. When both tests were
performed with the same plasma samples, their results
correlated with each other and with a third test, the TAT
assay (Table 3): In mice injected with 20 µg LPS i.p., 4/5
mice became positive in all three assays. When 300 U of
hirudin was injected in addition to 20 µg LPS, all but one
mouse in the Berichrom FM test, were negative for SF or
TAT in all three assays. Thus we confirmed the thrombin
specificity of the signals observed in the three assays.
SF was also measured in another model of systemic coag-
ulation activation: 2 U of thrombin were injected i.v. into
mice, and 7 out of 9 mice showed positive test results. The
remaining two mice probably failed to develop a systemic
coagulation activation because thrombin initiated a
strong local coagulation reaction in the tail vein, consum-
ing the vast majority of thrombin at the injection site.
I.v. injections of an inert solution can activate the 
coagulation system
Comparisons between untreated mice and mice treated
with 0.9% NaCl-solution (clinical grade) revealed that i.v.
injections can induce the formation of SF. Figure 2 dem-
Table 3: Correlation of results of three different assays determining thrombin activity in plasma of mice treated with 
lipopolysaccharides (LPS) in the presence and absence of the thrombin inhibitor hirudin
Soluble Fibrin 
determined by 
agglutination assay
Soluble Fibrin 
determined by 
chromogenic assay
Thrombin-Antithrombin complexes
Treatment of mice sample no. semiquantitative 
result*
qualitative result (fold 
increase over negative 
control)
qualitative result [ng/ml]
L P S ,  1 5  m i n1- -  ( 1 . 1 ) -3
2 - - (1.3) - 0
3 - - (1.1) - 2
4 (+) + (2.2) - 3
5 ++ + (3.7) - 8
LPS, 2 h 6 (+) - (1.2) - 6
7+ +  ( 2 . 2 ) + 2 1
8+ +  ( 2 . 2 ) + 3 4
9+ + +  ( 2 . 4 ) +2 0
10 ++ + (2.1) + 22
LPS + hirudin, 2 h 11 - + (2.2) - 10
1 2 --  ( 1 . 6 )- 1 0
1 3 --  ( 1 . 5 )- 1 0
14 (+) - (1.8) - 5
15 (+) - (1.8) - 5
no treatment 16 - - (1.5) - 2
1 7 --  ( 1 . 1 )- 0
1 8 --  ( 0 . 9 )- 0
* where ++ corresponds to 0.05 thrombin units/ml, + corresponds to 0.025 thrombin units/ml, (+) stands for borderline result (less than +, but not 
conclusively -) and – stands for negative (see also Figure 1C).Thrombosis Journal 2005, 3:21 http://www.thrombosisjournal.com/content/3/1/21
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onstrates that SF became detectable in 32 % of plasma
samples from mice after a slow i.v. injection of 0.4 ml
physiological NaCl-solution in comparison with 0% in
untreated mice. LPS-treated mice served as a positive con-
trol. This demonstrates that i.v. injection of an inert solu-
tion unrelated to the coagulation system can result in
systemic coagulation activation, likely by mechanically
damaging the venous wall. The agglutination test for SF
was sensitive enough to detect this reaction.
All test parameters become positive in a mouse model of 
systemic coagulation induction
As illustrated in Figure 3, all test parameters changed over
time, after injection of LPS. SF became positive at early
time points, TAT and free ATIII at later time points (6 h
and 24 h after LPS injection). The counts for WBC and PLT
showed a pattern, which was previously described for
humans [28], i.e. WBC counts fell initially, followed by an
increase above normal, and PLT counts were reduced. PT
rose after 24 hours, but not in all mice, therefore standard
deviations were high. aPTT was elevated as early as 2 h
post injection and continued to rise. Schistocyte counts
changed only slightly (from 3 to 6 fragments per field after
LPS injection and from 4 to 9 fragments per field after
tumor necrosis factor-alpha injection, data not shown). In
conclusion, all parameters tested here are suited for
detecting a systemic coagulation activation, with schisto-
cyte counts being the least sensitive.
WBC and PLT counts can be elevated in tumor bearing 
mice
We measured each of the laboratory parameters in several
subcutaneously growing tumor models and compared the
values to those of non-tumor bearing mice (Figure 4). In
the models tested, we did not find any significant changes
in laboratory parameters compared to control mice,
except for WBC and PLT. WBC counts were elevated in the
lymphoma model and PLT counts both in the myeloma
and the lymphoma model.
This argues against a procoagulant status in these models,
but would have to be evaluated separately for other tumor
models.
Selection of a panel of coagulation parameters for routine 
analysis
The selection of tests was based on the following criteria:
Sensitivity of the test, suitability for measuring systemic
coagulation activation, sample volume required and the
feasability for testing a large number of samples. The
required sample volume is even more critical in studies
with diseased mice, because in our experience the volume
of blood that can be obtained from sick mice is lower than
that from healthy mice.
In consequence, the measurement of PT and aPTT was not
included in the panel because i) a total of at least 100 µl
plasma (about 200 µl of blood) is needed for these two
tests; ii) it is well accepted that PT and aPTT are global
markers and not specific for systemic coagulation activa-
tion [40]; and iii) a comparison of aPTT results between
different laboratories is difficult [41].
Schistocyte counts are very labour intensive, somewhat
subjective, and did not prove to be very sensitive. There-
fore they were not included in the panel.
In contrast, SF and TAT indicate a systemic coagulation
activation and the required sample volumes are low (5 µl
and 20 µl of plasma, respectively). ATIII measures a differ-
ent parameter (consumption) with a different kinetics
and also requires a low sample volume (5 µl of plasma).
WBC and PLT, which can both be performed with a total
sample volume of 10 µl blood, have a known pattern of
change in DIC.
In conclusion, we propose SF, TAT, ATIII, WBC and PLT as
a useful panel of tests for systemic coagulation activation.
Occurrence of soluble fibrin (SF) in mice injected i.v. with  0.9% NaCl Figure 2
Occurrence of soluble fibrin (SF) in mice injected i.v. 
with 0.9% NaCl. The percent of mice, that became positive 
for soluble fibrin in the SF agglutination test after slow i.v. 
injection of physiological NaCl-solution (clinical grade), is 
plotted versus non-injected mice ("No Rx") and versus 
Lipopolysaccharide (LPS)-injected mice as a positive control. 
Black: percent positive, shaded: percent borderline, white: 
percent negative for SF.Thrombosis Journal 2005, 3:21 http://www.thrombosisjournal.com/content/3/1/21
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A VTA consisting of the extracellular domain of tissue 
factor targeted to VCAM-1 does not induce systemic 
coagulation activation
We then tested the impact of a VTA, which selectively
induces coagulation activation in tumor vasculature [5],
on coagulation parameters at different time points after
injection into tumor bearing mice. The results are illus-
trated in Figure 5 and demonstrate that there was no indi-
cation of systemic cogulation activation after treatment
with that particular VTA.
Discussion
Despite the importance of measuring coagulation param-
eters in preclinical treatment studies with VTAs, there have
been virtually no reports on this topic. This is predomi-
nantly due to technical challenges. Therefore our first task
was to select and refine tests for detection of systemic
coagulation activation in mice. Regarding technical issues,
we observed that sampling from the heart or tail vein
introduced artifacts in coagulation measurements. The
direct comparison of three different sampling techniques
demonstrated that tail cut and heart puncture appear to be
unsuitable for coagulation studies. This is due to tissue
damage, which results in artificial coagulation activation
leading to positive test results for early markers of coagu-
lation activation. Therefore, we propose Vena cava punc-
ture as the sampling method of choice. A second potential
source of coagulation activation is the application route.
Our observation that SF formation occurred after the slow
i.v. injection of an inert solution, is important since i.v.
injections are frequently used in preclinical studies. This
must be considered for the selection of appropriate nega-
tive controls and reference values.
Systemic coagulation activation can ultimately lead to dis-
seminated intravascular coagulation (DIC), a complex
thrombohemorrhagic disorder. Diagnosis of DIC is com-
plicated because there is no truly specific laboratory test
available. Various coagulation tests have been ranked in
terms of their reliability to detect DIC in the following
order [40]: 1. Prothrombin fragments 1 and 2, 2. Fibrin D-
dimer, 3. Antithrombin III, 4. Fibrinopeptide A, 5. Platelet
factor 4, 6. Fibrin degradation products, 7. Platelet counts,
8. Protamine test detecting SF, 9. thrombin time, 10.
fibrinogen, 11. PT, 12. aPTT. Since the commercially avail-
able assays for prothrombin fragments 1 and 2, fibrin D-
dimer, fibrinopeptide A, platelet factor 4 and fibrin degra-
dation products are not suited for the analysis of murine
samples (13, own data), we tested antithrombin III, TAT,
platelet counts and soluble fibrin. Soluble fibrin is diag-
nostic for thrombin action on fibrinogen and has been
described as an early marker for systemic coagulation acti-
vation [29-31]. This is the first study to describe the meas-
urement of SF in mice. We have adapted two
commercially available functional SF assays for this pur-
Changes of coagulation parameters in Lipopolysaccharide- induced endotoxemia Figure 3
Changes of coagulation parameters in Lipopolysac-
charide-induced endotoxemia. Mice were injected with 
50 µg Lipopolysaccharide (LPS) i.p. and coagulation parame-
ters were analyzed as described in the text. Black circles, left 
y-axis: TAT, ATIII, WBC, PT; White circles, right y-axis: SF, 
PLT, aPTT. Means and standard deviations (error bars) from 
groups of 3–15 mice are shown.
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Changes of coagulation parameters in tumor bearing mice Figure 4
Changes of coagulation parameters in tumor bearing mice. Tumor bearing mice were analyzed for coagulation param-
eters as described in the text in comparison with non-tumor bearing mice. CO: non-tumor bearing control mice; F: mice with 
F9 teratocarcinoma; C: mice with Colo677 myeloma; L5: mice with L540rec Hodgkin's lymphoma; H: mice with HT29 colon 
carcinoma; LS: mice with LS174T colon carcinoma; I: mice with IMR5 neuroblastoma. Means and standard deviations (error 
bars) from groups of 4–18 mice are shown. *: statistically significant versus control mice (p < 0.05).
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Changes of coagulation parameters after treatment with vascular targeting agent Figure 5
Changes of coagulation parameters after treatment with vascular targeting agent. Mice with Colo677 myeloma 
tumors were injected i.v. with a vascular targeting agent, consisting of the extracellular portion of tissue factor targeted to 
murine VCAM-1. Coagulation parameters were analyzed as described in the text. Black circles, left y-axis: TAT, ATIII, WBC. 
White circles, right y-axis: SF, PLT. Means and standard deviations (error bars) from groups of 3–6 mice are shown.
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pose. They correlated well with each other and with TAT
levels in a mouse model for DIC. Hirudin, a direct
thrombin inhibitor, abolished the response indicating
that the results were due to a specific action of thrombin.
We did not include the measurement of fibrinogen,
because it has been described to be neither sensitive nor
specific for systemic coagulation activation [42]. Since our
proposed sampling technique requires that for every time
point one mouse be sacrificed, it becomes important, that
all tests be performed with a reasonable sample volume.
Tests with different kinetics should be combined to
increase the probability for detection of systemic coagula-
tion activation at any given timepoint. Tests with low spe-
cificity for systemic coagulation activation or tests which
require high sample volumes are of lesser value, e.g. PT
and aPTT.
Based on the criteria of feasability and suitability we
selected the following panel of assays to detect systemic
coagulation activation: SF, TAT, ATIII, WBC and PLT. The
complete set of selected tests can be performed with 50 µl
of plasma, the tests are suited for testing in a large number
of samples, they all become positive in a mouse model of
DIC, and they are generally available.
We then analyzed the impact of tumors on the murine
coagulation status. In the tumor models used here there
were no significant changes in most of the coagulation
parameters, but this remains to be validated separately for
each tumor model used.
We have since applied this panel routinely in preclinical
studies with VTAs developed in our laboratory, and one
example is presented. For that particular VTA, all coagula-
tion parameters stayed within normal range over the
entire time period tested.
Conclusion
Vascular targeting is a new and promising approach for
the therapy of cancer and other diseases. Clinical studies
have revealed, that there is a potential for side effects in
the coagulation system. Therefore, it is essential to prede-
termine these potential side effects in preclinical studies.
Testing of coagulation parameters in mice, the most fre-
quently used species for these trials, has so far been
reserved to specialized laboratories. In this study a panel
of assays and optimized methods for measuring systemic
coagulation activation in murine samples is presented.
The panel was applied on tumor bearing mice and on
mice treated with a VTA. We suggest its general use for
coagulation activation analysis in mice.
Methods
Blood sampling
Three different techniques were used: Vena cava puncture,
heart puncture and tail cutting. If not otherwise specified,
blood was drawn from the Vena cava.
For Vena cava or heart puncture, mice were anaesthetized
with ether, the thoracical cavity was opened, and blood
was drawn from the upper Vena cava or from the heart
into a syringe containing sodium citrate (1/10 or 1/5 vol-
ume of 3.1% sodium citrate). For tail cutting, mice were
warmed up under an infrared lamp (250 W) for one
minute. The tail was cut with a scalpel, the first three drops
of blood were not used, and then blood was collected into
a heparin-coated centrifuge tube, which contained
sodium citrate (see above). After removing blood for
blood cell counts (WBC, PLT, schistocytes), citrated blood
was centrifuged twice (500 g and 8000 g) to remove plate-
lets. Platelet-poor plasma was analyzed immediately for
soluble fibrin and the remainder of the samples were fro-
zen at -80°C until further use.
Negative control plasma
Negative control mice were either untreated mice or mice
injected with 0.9% NaCl-solution (clinical grade). In
some experiments pooled plasma was used, which was
prepared as follows: Blood from 20 mice was drawn by
Vena cava puncture and platelet-poor plasma was
obtained as described above. In rare cases the sampling
technique could produce outliers. In order to exclude
these artifacts from our negative control pool, each sam-
ple was tested for soluble fibrin and for thrombin-anti-
thrombin complexes (method see below). The vast
majority of samples were negative in these tests, and those
samples were pooled. The pool was frozen in aliquots at -
80°C.
Measurement of soluble fibrin (SF) in mice
As a positive control, we incubated either purified human
fibrinogen or human and murine plasma samples with
0.02 mU/ml bovine thrombin (Dade Behring, Lieder-
bach, Germany). To prove the formation of crosslinked
fibrin and fibrin-dimers, Western blotting of digested
plasma or fibrinogen samples was performed. Samples
were separated by SDS-PAGE (sodium dodecyl-sulfate
polyacrylamide-gel electrophoresis) followed by capillary
heat transfer onto nitrocellulose membranes. Membranes
were stained with a polyclonal sheep-anti-rabbit
fibrin(ogen) antibody (Haemochrom, Essen, Germany),
known to be crossreactive with mouse and human
fibrin(ogen), followed by chemiluminescent detection.
SF in plasma was then measured with two functional
assays: i) a modification of a commercially available
agglutination assay (FM-test, Roche-Diagnostics, Man-Thrombosis Journal 2005, 3:21 http://www.thrombosisjournal.com/content/3/1/21
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nheim, Germany) which measures the agglutination reac-
tion of SF with fibrin monomer-coated erythrocytes and
ii) a modification of a chromogenic assay (Berichrom FM
assay, Dade Behring), which is based on the ability of SF
to enhance the tissue plasminogen activator (tPA)-
induced plasminogen conversion. For the modified agglu-
tination test, 5 µl of citrated mouse plasma were diluted
in 100 µl of Owren's buffer (28 mM sodium barbital in
125 mM sodium chloride solution, pH = 7.35), and
mixed on a slide (provided in the kit) with 50 µl of the
erythrocyte suspension. After incubation at 37°C for 10
minutes, samples were mixed again and the agglutination
reaction compared with positive and negative control
samples. Positive controls were mouse plasma samples
treated with 0.02 U/ml thrombin (Dade Behring), nega-
tive controls were untreated normal mouse plasma sam-
ples. For the chromogenic assay, 250 µl of human mini-
plasminogen solution (provided in the kit) were pipetted
into the wells of a 96 well microtiter plate, and the plate
was preheated to 37°C. A standard curve was generated by
incubating murine plasma samples with different
amounts (2 mU/ml – 100 mU/ml) of bovine thrombin.
5µl samples and controls were added to the plasminogen-
solution, and 50 µl tPA reagent was pipetted to each well
with a multichannel pipettor. Samples were incubated at
37°C for 5 minutes, then 25 µl of plasmin substrate was
added with a multichannel pipettor and absorption at
405 nm (minus 650 nm) was measured kinetically in an
ELISA reader. The tests were also carried out with
thrombin-treated or untreated human plasma.
To verify that the test results were due to the action of
thrombin, we added the specific thrombin inhibitor hiru-
din. Hirudin (Roche, Mannheim, Germany) was either
mixed in vitro at a concentration of 1.4 U/ml with the pos-
itive control samples, or injected in addition to LPS in the
in vivo studies (see below).
Other assays for coagulation parameters
For platelet and white blood cell counts, citrated blood
was mixed with 1% (w/v) ammonium-oxalate (for plate-
let counts) or with 3% (v/v) acetic acid (for white blood
cell counts) at a dilution of 1:20, and incubated on a
shaker for 10 min. Platelets and white blood cells were
then counted under a light microscope at 400 × magnifi-
cation in a counting chamber (type Neubauer Improved).
For schistocyte quantification, thin blood smears were
prepared from full blood. Smears were dried and stained
with the Pappenheim Method: Fixation in 100% (v/v)
methanol, followed by 5 minutes staining in May-Grün-
wald solution (Sigma-Aldrich, St. Louis, MO) and 30 min-
utes in Giemsa solution (Sigma-Aldrich). Schistocytes
were counted in three high power fields at 400 × magnifi-
cation on a light microscope. Prothrombin time (PT) and
activated partial thromboplastin time (aPTT) were auto-
matically measured on a BCS coagulation analyzer (Dade
Behring) using the Innovin kit (Dade Behring) for PT, the
Actin FS kit (Dade Behring) for aPTT and normal human
plasma (SHP, Dade Behring) as a standard. Thrombin-
antithrombin complexes (TAT complexes) were measured
using an ELISA test (Enzygnost-TAT, Dade Behring)
according to the manufacturer's instructions, but using 20
µl of plasma samples and standards. This test is fully cross-
reactive with murine samples [13]. Briefly, microtiter-
plates which were coated with an anti-thrombin antibody
were incubated with samples and standards (provided in
the kit), washed, incubated with a peroxidase-conjugated
anti-Antithrombin III antibody, washed and detected
with OPD (o-phenylene-diamine-dihydrochloride) sub-
strate. Absorption was measured on an ELISA reader. Nor-
mal platelet poor mouse plasma was used as a negative
control. Antithrombin III (ATIII) was measured using a
functional antithrombin test (Coamatic-Antithrombin,
Chromogenix, Milano, Italy) according to the manufac-
turer's instructions, using 5 µl plasma and standards per
test at the recommended dilutions. Briefly, plasma sam-
ples and standards (provided in the kit) were incubated
with an excess of coagulation factor Xa in the presence of
heparin. The residual factor Xa was quantified with a chro-
mogenic substrate specific for coagulation factor Xa and
the decrease of absorption was measured on an ELISA
reader. Normal platelet poor mouse plasma was used as a
standard to define 100% activity.
Mouse models of systemic coagulation induction
Mice were injected either i.v. with 2 U bovine thrombin
(Dade Behring) or i.p. with 20 µg or 50 µg lipopolysaccha-
rides (LPS from E.coli serotype 055:B5, Sigma-Aldrich).
For schistocyte counts, mice were injected with 20 µg LPS
i.p. or with 100 µg tumor necrosis factor-alpha i.v. After
specified time periods, citrated blood was drawn and ana-
lyzed for coagulation parameters as described above. In
the cases where thrombin action was to be inhibited, 300
U hirudin were injected i.v. prior to 20 µg LPS.
Tumor models
Immunodeficient mice were injected s.c. with 1 × 107
tumor cells. Tumor cell lines used were: F9 murine terato-
carcinoma cells (ECACC, Salisbury, UK), Colo 677
human myeloma cells (DSMZ, Braunschweig, Germany),
L540rec human Hodgkin's lymphoma cells [43], HT29
human colon carcinoma cells (ATCC/LGC, Middlesex,
UK), LS174T human colon carcinoma cells (ATCC), IMR5
human neuroblastoma cells (kindly provided by Dr.
Unwicker, University of Marburg, Germany). Mice were
analyzed for coagulation parameters when tumors had
reached a size of 150–500 µl. Differences between groups
were analyzed for statistical significance with the Mann-
Whitney U test for unpaired groups. The term "signifi-
cant" was used, where p-values were less than 0.05.Thrombosis Journal 2005, 3:21 http://www.thrombosisjournal.com/content/3/1/21
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Coagulation parameters after treatment of tumor bearing 
mice with a VTA
Mice bearing Colo677 tumors were treated with a VTA
developed in our laboratory. It consisted of a single chain
variable fragment antibody (scFv) directed against murine
vascular cellular adhesion molecule-1 (VCAM-1), which
was expressed on tumor endothelial cells, and the extra-
cellular domain of tissue factor. This fusion protein
induces selective coagulation activation in the tumor vas-
culature [5]. One single dose of 20 µg was administered
i.v. Mice were sacrificed at specified timepoints after treat-
ment, and analysis of coagulation parameters was per-
formed as described above.
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